Abstract

Retinoblastoma-binding protein 1 (RBBP1), also named AT-rich interaction domain containing 4A (ARID4A), is a tumor and leukemia suppressor involved in epigenetic regulation in leukemia and Prader-Willi/Angelman syndromes. Although the involvement in epigenetic regulation is proposed to involve its chromobarrel and/or Tudor domains because of their potential binding to methylated histone tails, the structures of these domains and their interactions with methylated histone tails are still uncharacterized. In this work, we first found that RBBP1 contains five domains by bioinformatics analysis. Three of the five domains, i.e. chromobarrel, Tudor, and PWWP domains, are Royal Family domains, which potentially bind to methylated histone tails. We further purified these domains and characterized their interaction with methylated histone tails by NMR titration experiments. Among the three Royal Family domains, only the chromobarrel domain could recognize trimethylated H4K20 (with an affinity of ∼3 mm), as well as recognizing trimethylated H3K9, H3K27, and H3K36 (with lower affinities). The affinity could be further enhanced up to 15-fold by the presence of DNA. The structure of the chromobarrel domain of RBBP1 determined by NMR spectroscopy has an aromatic cage. Mutagenesis analysis identified four aromatic residues of the cage as the key residues for methylated lysine recognition. Our studies indicate that the chromobarrel domain of RBBP1 is responsible for recognizing methylated histone tails in chromatin remodeling and epigenetic regulation, which presents a significant advance in our understanding of the mechanism and relationship between RBBP1-related gene suppression and epigenetic regulation.

Highlights

  • Retinoblastoma-binding protein 1 (RBBP1), a tumor suppressor, is involved in epigenetic regulation in cancer

  • Our studies indicate that the chromobarrel domain of RBBP1 is responsible for recognizing methylated histone tails in chromatin remodeling and epigenetic regulation, which presents a significant advance in our understanding of the mechanism and relationship between RBBP1-related gene suppression and epigenetic regulation

  • Combining the results of the secondary structure prediction, the disorder prediction, and the sequence alignment of RBBP1 and RBBP1L1, we found that RBBP1 and RBBP1L1 each contain five structural domains: a Tudor domain (TD, residues 1–121), a PWWP domain (PD, previously named RBB1NT domain, residues 170 –273), an AT-rich interaction domain (ARID) domain (AD, residues 307– 411), a chromobarrel domain (CD, residues 568 – 635) and a C-terminal R2 domain (Fig. 1)

Read more

Summary

Background

Retinoblastoma-binding protein 1 (RBBP1), a tumor suppressor, is involved in epigenetic regulation in cancer. Three of the five domains, i.e. chromobarrel, Tudor, and PWWP domains, are Royal Family domains, which potentially bind to methylated histone tails. A large number of Royal Family domains have been found in various epigenetic-related proteins and they recognize methylated histone tails with different affinities and specificities [13]. We analyzed the domain organization of RBBP1 by bioinformatics and found that RBBP1 contains three Royal Family domains, i.e. a Tudor domain (TD), a PWWP domain (PD), and a chromobarrel domain (CD) We found that these domains could fold independently and that there is no direct interaction between them. To explore the structural basis of the epigenetic regulation function of RBBP1, we detected the interaction of the three Royal Family domains of RBBP1 with methylated histone tails using NMR titration techniques. We found that the positively charged surface around the aromatic cage of the RBBP1 CD can interact with DNA and that the presence of DNA enhances significantly the recognition of methylated histones

EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.